Introduction
This study explored the effects of supplementing patients with early-stage age-related macular degeneration (AMD) using three different macular carotenoid formulations, lutein, zeaxanthin, and meso-zeaxanthin. The primary focus was not only on increasing macular pigment but also on assessing improvements in visual function, particularly contrast sensitivity, which is crucial for patients with AMD.
Why was the research undertaken?
While previous research had shown that carotenoid supplementation could increase macular pigment, the impact on actual vision-related functional outcomes in AMD patients was unclear. We aimed to investigate whether these supplements could improve visual performance in patients with early AMD, with contrast sensitivity as the key measure.
How was the study conducted?
Patients diagnosed with early AMD received one of three macular carotenoid supplement formulations over 12 months. Throughout the study, visual function tests including contrast sensitivity and macular pigment density measurements were conducted to evaluate the efficacy of the supplements.
What were the results?
The formulation containing all three carotenoids, lutein, zeaxanthin, and meso-zeaxanthin, resulted in the greatest increase in macular pigment and a significant improvement in contrast sensitivity among patients. This was the first time that a clear enhancement in visual function was demonstrated in an AMD patient group following carotenoid supplementation. The inclusion of meso-zeaxanthin proved critical to achieving these superior outcomes.
What is the societal benefit?
These findings have significant clinical implications. By demonstrating that a supplement including meso-zeaxanthin can improve both macular pigment and visual function in early AMD patients, this research supports targeted nutritional strategies to enhance vision-related quality of life. Clinicians should consider recommending formulations containing all three macular carotenoids to maximize patient benefit and potentially slow vision loss in AMD.
